» Articles » PMID: 34354057

Activation Pathway of a G Protein-coupled Receptor Uncovers Conformational Intermediates As Targets for Allosteric Drug Design

Overview
Journal Nat Commun
Specialty Biology
Date 2021 Aug 6
PMID 34354057
Citations 85
Authors
Affiliations
Soon will be listed here.
Abstract

G protein-coupled receptors (GPCRs) are the most common proteins targeted by approved drugs. A complete mechanistic elucidation of large-scale conformational transitions underlying the activation mechanisms of GPCRs is of critical importance for therapeutic drug development. Here, we apply a combined computational and experimental framework integrating extensive molecular dynamics simulations, Markov state models, site-directed mutagenesis, and conformational biosensors to investigate the conformational landscape of the angiotensin II (AngII) type 1 receptor (AT receptor) - a prototypical class A GPCR-activation. Our findings suggest a synergistic transition mechanism for AT receptor activation. A key intermediate state is identified in the activation pathway, which possesses a cryptic binding site within the intracellular region of the receptor. Mutation of this cryptic site prevents activation of the downstream G protein signaling and β-arrestin-mediated pathways by the endogenous AngII octapeptide agonist, suggesting an allosteric regulatory mechanism. Together, these findings provide a deeper understanding of AT receptor activation at an atomic level and suggest avenues for the design of allosteric AT receptor modulators with a broad range of applications in GPCR biology, biophysics, and medicinal chemistry.

Citing Articles

Computational Elucidation of a Monobody Targeting the Phosphatase Domain of SHP2.

Wang Y, Qiao X, Zhu R, Zhou L, Zhang Q, Lu S Biomolecules. 2025; 15(2).

PMID: 40001520 PMC: 11853358. DOI: 10.3390/biom15020217.


A novel allosteric driver mutation of β-glucuronidase promotes head and neck squamous cell carcinoma progression through STT3B-mediated PD-L1 N-glycosylation.

Liu Z, Meng X, Tang X, Zhang J, Zhang Z, He Y MedComm (2020). 2025; 6(2):e70062.

PMID: 39830021 PMC: 11742429. DOI: 10.1002/mco2.70062.


Molecular basis of lipid and ligand regulation of prostaglandin receptor DP2.

Xu J, Xu Y, Hou L, He X, Li Y, Zhao J Proc Natl Acad Sci U S A. 2024; 121(51):e2403304121.

PMID: 39665758 PMC: 11665870. DOI: 10.1073/pnas.2403304121.


Exploring key features of selectivity in somatostatin receptors through molecular dynamics simulations.

Guccione C, Gervasoni S, Ozturk I, Bosin A, Ruggerone P, Malloci G Comput Struct Biotechnol J. 2024; 23:1311-1319.

PMID: 39660216 PMC: 11630666. DOI: 10.1016/j.csbj.2024.03.005.


AlphaFold3 versus experimental structures: assessment of the accuracy in ligand-bound G protein-coupled receptors.

He X, Li J, Shen S, Xu H Acta Pharmacol Sin. 2024; .

PMID: 39643640 DOI: 10.1038/s41401-024-01429-y.


References
1.
Wu Y, Tong J, Ding K, Zhou Q, Zhao S . GPCR Allosteric Modulator Discovery. Adv Exp Med Biol. 2019; 1163:225-251. DOI: 10.1007/978-981-13-8719-7_10. View

2.
Liu J, Horst R, Katritch V, Stevens R, Wuthrich K . Biased signaling pathways in β2-adrenergic receptor characterized by 19F-NMR. Science. 2012; 335(6072):1106-10. PMC: 3292700. DOI: 10.1126/science.1215802. View

3.
Klein Herenbrink C, Sykes D, Donthamsetti P, Canals M, Coudrat T, Shonberg J . The role of kinetic context in apparent biased agonism at GPCRs. Nat Commun. 2016; 7:10842. PMC: 4770093. DOI: 10.1038/ncomms10842. View

4.
van der Westhuizen E, Breton B, Christopoulos A, Bouvier M . Quantification of ligand bias for clinically relevant β2-adrenergic receptor ligands: implications for drug taxonomy. Mol Pharmacol. 2013; 85(3):492-509. DOI: 10.1124/mol.113.088880. View

5.
Hu Q, Dong J, Du H, Zhang D, Ren H, Ma M . Constitutive Gαi coupling activity of very large G protein-coupled receptor 1 (VLGR1) and its regulation by PDZD7 protein. J Biol Chem. 2014; 289(35):24215-25. PMC: 4148852. DOI: 10.1074/jbc.M114.549816. View